| Ytd | -86.56% | |
| 1y | -97.96% |
| Open | 2.53 | Prev Close | 2.51 | Low | 2.53 | High | 2.61 | Mkt Cap | 1.05M |
| Vol | 2.82K | Avg Vol | 640.88K | EPS | -39.55 | P/E | -0.06 | Forward P/E | -3.95 |
| Beta | -0.26 | Short Ratio | 0.23 | Inst. Own | 8.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 3.54 | 200-d Avg | 16.83 | 1yr Est | 9.00 |
SLXN News
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-
CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by
Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Comp
Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expect
US stocks mixed, Nasdaq up 0.39% as Dow down 0.03%. Target Corp beats earnings, oil down 2.4% and mo
Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204
Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion
Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clin
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic c
Silexion Therapeutics Corp (NASDAQ: SLXN - Get Free Report) was down 0.9% during mid-day trading on
Significant regulatory milestone marks advancement into clinical-stage development of next-generatio
Significant regulatory milestone marks advancement into clinical-stage development of next-generatio
Throughout the year, the Company reported significant positive preclinical findings for SIL204 acros
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial i
Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexi
Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advanci
Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 202
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhib
Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Co